Dr. Walter joined Immatics Biotechnologies GmbH in 2005 where he became VP Immunology. For over 15 years he has been active in the field of cancer immunotherapy and a leader in human T-cell biology. In addition to supporting the development of the PRESIDENT technology platform, under his leadership, Immatics developed its powerful Immunomonitoring and T-cell receptor (TCR) discovery platforms to support the generation of safe and effective T-cell-based therapeutic modalities.
In 2015, Dr. Walter established operations of Immatics US, Inc. in Houston, Texas in close collaboration with MD Anderson Cancer Center (MDACC) as Chief Scientific Officer to develop next-generation adoptive cell therapies (ACT). He contributed significantly to raising the necessary funding including a $20m CPRIT grant by the State of Texas. Dr. Walter leads a team that is responsible for Product Science, Process Development, Manufacturing, Quality Control and Program Management for Immatics’ cell therapy programs. He gained his Ph.D. in Immunology from the University of Tuebingen, Germany.